- Home
- FIVE vs MDGL Comparison
FIVE vs MDGL Comparison
Compare FIVE & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIVE
- MDGL
- Stock Information
- Founded
- FIVE 2002
- MDGL 2011
- Country
- FIVE United States
- MDGL United States
- Employees
- FIVE N/A
- MDGL N/A
- Industry
- FIVE Department/Specialty Retail Stores
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- FIVE Consumer Discretionary
- MDGL Health Care
- Exchange
- FIVE Nasdaq
- MDGL Nasdaq
- Market Cap
- FIVE 6.1B
- MDGL 6.8B
- IPO Year
- FIVE 2012
- MDGL N/A
- Fundamental
- Price
- FIVE $117.51
- MDGL $272.67
- Analyst Decision
- FIVE Buy
- MDGL Strong Buy
- Analyst Count
- FIVE 19
- MDGL 10
- Target Price
- FIVE $99.29
- MDGL $420.63
- AVG Volume (30 Days)
- FIVE 1.9M
- MDGL 306.5K
- Earning Date
- FIVE 06-04-2025
- MDGL 05-01-2025
- Dividend Yield
- FIVE N/A
- MDGL N/A
- EPS Growth
- FIVE N/A
- MDGL N/A
- EPS
- FIVE 4.60
- MDGL N/A
- Revenue
- FIVE $3,876,527,000.00
- MDGL $317,383,000.00
- Revenue This Year
- FIVE $14.15
- MDGL $285.43
- Revenue Next Year
- FIVE $9.40
- MDGL $63.77
- P/E Ratio
- FIVE $25.34
- MDGL N/A
- Revenue Growth
- FIVE 8.91
- MDGL N/A
- 52 Week Low
- FIVE $52.38
- MDGL $200.63
- 52 Week High
- FIVE $141.70
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- FIVE 73.78
- MDGL 37.25
- Support Level
- FIVE $105.11
- MDGL $265.20
- Resistance Level
- FIVE $118.95
- MDGL $275.54
- Average True Range (ATR)
- FIVE 4.02
- MDGL 11.33
- MACD
- FIVE 0.52
- MDGL -0.64
- Stochastic Oscillator
- FIVE 91.82
- MDGL 18.64
About FIVE Five Below Inc.
Five Below Inc is a specialty value retailer offering merchandise targeted at the tween and teen demographic. The Company's edited assortment of products includes select brands and licensed merchandise. It derives revenue from sales of the Company's merchandise to customers.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.